About

History of Nasodine

Nasodine® Nasal Spray was developed over more than 10 years by an Australian biotechnology company, Firebrick Pharma Ltd.

Nasodine has been assessed now in six independently-controlled human clinical trials and its safety and use are supported by a growing list of peer-reviewed publications.

Firebrick Pharma owns several patents covering the formulation and uses of Nasodine. The Nasodine® trademark is registered internationally by Firebrick Pharma.

2012 Founding

Firebrick Pharma was founded with the mission to develop a PVP-iodine nasal spray to kill germs in the nose.
2014-2017 Development

Development commences to create a stable nasal formulation and packaging. International patent granted on the intranasal use of PVP-iodine.
2018-2023 Human Clinical trials

Phase 1, 2 and 3 human clinical trials show that Nasodine is safe to use in the nose 4 times daily for 5 days.
2024 Nasodine international launch

Nasodine Nasal Spray becomes available for sale in selected markets, including Singapore.

Nasodine Nasal Spray is your confident choice for nasal hygiene

Power of povidone-iodine in a nasal spray
Shown in laboratory studies to kill germs that can cause nasal infections.
Commuting and crowds may be hotspots for germs
Nasodine kills germs and can help protect your nasal health.
The right choice for healthcare professionals
Backed by 10 years of research, multiple human clinical trials and peer-reviewed publications.